Sonoma Capital Surpluse from 2010 to 2024
| SNOA Stock | USD 2.93 0.08 2.81% |
Capital Surpluse | First Reported 2011-06-30 | Previous Quarter 189.1 M | Current Value 189.2 M | Quarterly Volatility 16.5 M |
Check Sonoma Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Sonoma Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 296.7 K, Interest Expense of 13.7 K or Selling General Administrative of 13.3 M, as well as many indicators such as Price To Sales Ratio of 0.1, Dividend Yield of 0.0 or PTB Ratio of 0.24. Sonoma financial statements analysis is a perfect complement when working with Sonoma Pharmaceuticals Valuation or Volatility modules.
Sonoma | Capital Surpluse |
Latest Sonoma Pharmaceuticals' Capital Surpluse Growth Pattern
Below is the plot of the Capital Surpluse of Sonoma Pharmaceuticals over the last few years. It is Sonoma Pharmaceuticals' Capital Surpluse historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Sonoma Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| Capital Surpluse | 10 Years Trend |
|
Capital Surpluse |
| Timeline |
Sonoma Capital Surpluse Regression Statistics
| Arithmetic Mean | 174,106,011 | |
| Geometric Mean | 172,982,695 | |
| Coefficient Of Variation | 11.82 | |
| Mean Deviation | 17,244,010 | |
| Median | 176,740,000 | |
| Standard Deviation | 20,573,172 | |
| Sample Variance | 423.3T | |
| Range | 68.5M | |
| R-Value | 0.94 | |
| Mean Square Error | 57.3T | |
| R-Squared | 0.87 | |
| Slope | 4,301,481 | |
| Total Sum of Squares | 5925.6T |
Sonoma Capital Surpluse History
About Sonoma Pharmaceuticals Financial Statements
Sonoma Pharmaceuticals stakeholders use historical fundamental indicators, such as Sonoma Pharmaceuticals' Capital Surpluse, to determine how well the company is positioned to perform in the future. Although Sonoma Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. For example, changes in Sonoma Pharmaceuticals' assets and liabilities are reflected in the revenues and expenses on Sonoma Pharmaceuticals' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Sonoma Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Capital Surpluse | 217.6 M | 189.6 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Sonoma Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Sonoma Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Sonoma Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Sonoma Pharmaceuticals Stock:Check out the analysis of Sonoma Pharmaceuticals Correlation against competitors. For information on how to trade Sonoma Stock refer to our How to Trade Sonoma Stock guide.You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sonoma Pharmaceuticals. If investors know Sonoma will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sonoma Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.99) | Revenue Per Share 20.967 | Quarterly Revenue Growth (0.01) | Return On Assets (0.20) | Return On Equity (0.75) |
The market value of Sonoma Pharmaceuticals is measured differently than its book value, which is the value of Sonoma that is recorded on the company's balance sheet. Investors also form their own opinion of Sonoma Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Sonoma Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sonoma Pharmaceuticals' market value can be influenced by many factors that don't directly affect Sonoma Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sonoma Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Sonoma Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sonoma Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.